Valbiotis
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12f Rue Paul Vatine, Perigny, Nouvelle-A...Phone Number
+33 546286258Website
www.valbiotis.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs. Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic and cardiovascular diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources. Its products are intended to be licensed to players in the health sector. Created at the beginning of 2014 in La Rochelle, the company has forged numerous partnerships with leading academic centers. The company has established three sites in France - Périgny, La Rochelle (17) and Riom (63) - and a subsidiary in Quebec City (Canada). Valbiotis is a member of the BPI Excellence network and has been recognized as an Innovative Company by the BPI label. Valbiotis has also been awarded Young InnovativRead more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Valbiotis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Valbiotis has new funding data
Valbiotis, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Valbiotis has recently received funding, and reach out quickly before it becomes old news!
Click to see if Valbiotis had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Valbiotis
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Valbiotis launches new products
Check out if Valbiotis is spiking on competitors!
Earning: See what the market has to say on Valbiotis recently announced quarterly report
Recommended Actions
Find VP level buyers at Valbiotis
Find more new buyers
Company Profile Activity
Activity Insights
Valbiotis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Valbiotis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Valbiotis.
Valbiotis Tech Stack
A closer look at the technologies used by Valbiotis
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Medical Research
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Left Company
Open Position
Executive Move
Executive Moves
Valbiotis News & Media
Valbiotis announces the release of the Universal Registration Document
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) April 26, 2023. This document is made available to the public free of charge under the conditions providedValbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its results for fiscal year 2022 and reviews its clinical and scientific news and recent strategic advances. Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, comments: "During the year 20Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the last visit of the last patient enrolled in the Phase II/III REVERSE-IT study on the active substance TOTUM•63. This international, multi-center, randomized, placebo-controlled study on 600 untreated prValbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar. In this new edition you will find: The message from Sébastien PELTIER, CEO and co-founder of Valbiotis, to shareholders, who provide invaluable
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Valbiotis
Sign Up For FreeTo access detailed company insights
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs. Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of... Read More
